Literature DB >> 20679727

Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.

Zhe Jiang1, Tao Deng, Robert Jones, Huiqin Li, Jason I Herschkowitz, Jeff C Liu, Victor J Weigman, Ming-Sound Tsao, Timothy F Lane, Charles M Perou, Eldad Zacksenhaus.   

Abstract

Breast cancer is a highly heterogeneous disease, with several different subtypes being characterized by distinct histology, gene expression patterns, and genetic alterations. The tumor suppressor gene retinoblastoma 1 (RB1) is frequently lost in both luminal-B and triple-negative tumor (TNT; i.e., estrogen receptor-, progesterone receptor-, and human epidermal growth factor receptor 2-negative) breast cancer subtypes. However, a causal role for RB1 loss in different subtypes remains undefined. Here we report that deletion of Rb alone or together with its relative p107 in mouse mammary stem/bipotent progenitor cells induced focal acinar hyperplasia with squamous metaplasia. These lesions progressed into histologically diverse, transplantable mammary tumors with features of either luminal-B or TNT subtypes. The TNTs included basal-like tumors as well as tumors that exhibited epithelial-to-mesenchymal transition (EMT). The EMT-type tumors and a subset of the basal-like tumors, but not luminal-B-like tumors, expressed mutant forms of the tumor suppressor p53. Accordingly, targeted deletion of both Rb and p53 in stem/bipotent progenitors led to histologically uniform, aggressive, EMT-type tumors. Reintroduction of Rb into these tumor cells suppressed growth in vitro and tumor formation in vivo. These results establish a causal role for Rb loss in breast cancer in mice and demonstrate that cooperating oncogenic events, such as mutations in p53, dictate tumor subtype after Rb inactivation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20679727      PMCID: PMC2929714          DOI: 10.1172/JCI41490

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  81 in total

Review 1.  Oncogene addiction.

Authors:  I Bernard Weinstein; Andrew Joe
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

2.  Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype.

Authors:  David Sarrió; Socorro María Rodriguez-Pinilla; David Hardisson; Amparo Cano; Gema Moreno-Bueno; José Palacios
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

Review 3.  Structural and functional basis for therapeutic modulation of p53 signaling.

Authors:  Emily A Bassett; Wenge Wang; Farzan Rastinejad; Wafik S El-Deiry
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

4.  Association of chromosome band 8q22 copy number gain with high grade invasive breast carcinomas by assessment of core needle biopsies.

Authors:  Logan C Walker; Gavin C Harris; J Elisabeth Wells; Bridget A Robinson; Christine M Morris
Journal:  Genes Chromosomes Cancer       Date:  2008-05       Impact factor: 5.006

Review 5.  Triple-negative breast cancer: risk factors to potential targets.

Authors:  Bryan P Schneider; Eric P Winer; William D Foulkes; Judy Garber; Charles M Perou; Andrea Richardson; George W Sledge; Lisa A Carey
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

6.  Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition.

Authors:  Yoshimi Arima; Yasumichi Inoue; Tatsuhiro Shibata; Hidemi Hayashi; Osamu Nagano; Hideyuki Saya; Yoichi Taya
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

7.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

Authors:  Sven Rottenberg; Janneke E Jaspers; Ariena Kersbergen; Eline van der Burg; Anders O H Nygren; Serge A L Zander; Patrick W B Derksen; Michiel de Bruin; John Zevenhoven; Alan Lau; Robert Boulter; Aaron Cranston; Mark J O'Connor; Niall M B Martin; Piet Borst; Jos Jonkers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-29       Impact factor: 11.205

8.  The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.

Authors:  Jason I Herschkowitz; Xiaping He; Cheng Fan; Charles M Perou
Journal:  Breast Cancer Res       Date:  2008-09-09       Impact factor: 6.466

9.  Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis.

Authors:  Timothy A Chan; Sabine Glockner; Joo Mi Yi; Wei Chen; Leander Van Neste; Leslie Cope; James G Herman; Victor Velculescu; Kornel E Schuebel; Nita Ahuja; Stephen B Baylin
Journal:  PLoS Med       Date:  2008-05-27       Impact factor: 11.069

10.  Re-evaluation of mammary stem cell biology based on in vivo transplantation.

Authors:  Gilbert H Smith; Daniel Medina
Journal:  Breast Cancer Res       Date:  2008-02-25       Impact factor: 6.466

View more
  83 in total

Review 1.  Regulation of stem cell plasticity: mechanisms and relevance to tissue biology and cancer.

Authors:  Robert Strauss; Petra Hamerlik; André Lieber; Jiri Bartek
Journal:  Mol Ther       Date:  2012-02-07       Impact factor: 11.454

Review 2.  The retinoblastoma tumor suppressor and stem cell biology.

Authors:  Julien Sage
Journal:  Genes Dev       Date:  2012-07-01       Impact factor: 11.361

Review 3.  How to Choose a Mouse Model of Breast Cancer, a Genomic Perspective.

Authors:  Matthew R Swiatnicki; Eran R Andrechek
Journal:  J Mammary Gland Biol Neoplasia       Date:  2019-06-21       Impact factor: 2.673

4.  Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment.

Authors:  Agnieszka K Witkiewicz; Dayana B Rivadeneira; Adam Ertel; Jessica Kline; Terry Hyslop; Gordon F Schwartz; Paolo Fortina; Erik S Knudsen
Journal:  Am J Pathol       Date:  2011-07-12       Impact factor: 4.307

5.  Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.

Authors:  Patrick J Roberts; Jerry E Usary; David B Darr; Patrick M Dillon; Adam D Pfefferle; Martin C Whittle; James S Duncan; Soren M Johnson; Austin J Combest; Jian Jin; William C Zamboni; Gary L Johnson; Charles M Perou; Norman E Sharpless
Journal:  Clin Cancer Res       Date:  2012-08-07       Impact factor: 12.531

6.  RB in breast cancer: differential effects in estrogen receptor-positive and estrogen receptor-negative disease.

Authors:  Elizabeth A Musgrove; Robert L Sutherland
Journal:  Cell Cycle       Date:  2010-12-01       Impact factor: 4.534

7.  FoxM1 regulates mammary luminal cell fate.

Authors:  Janai R Carr; Megan M Kiefer; Hyun Jung Park; Jing Li; Zebin Wang; Joel Fontanarosa; Danielle DeWaal; Dragana Kopanja; Elizaveta V Benevolenskaya; Grace Guzman; Pradip Raychaudhuri
Journal:  Cell Rep       Date:  2012-06-07       Impact factor: 9.423

8.  Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer.

Authors:  Keli Xu; Jerry Usary; Philaretos C Kousis; Aleix Prat; Dong-Yu Wang; Jessica R Adams; Wei Wang; Amanda J Loch; Tao Deng; Wei Zhao; Robert Darrell Cardiff; Keejung Yoon; Nicholas Gaiano; Vicki Ling; Joseph Beyene; Eldad Zacksenhaus; Tom Gridley; Wey L Leong; Cynthia J Guidos; Charles M Perou; Sean E Egan
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

9.  RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.

Authors:  Robert A Jones; Tyler J Robinson; Jeff C Liu; Mariusz Shrestha; Veronique Voisin; YoungJun Ju; Philip E D Chung; Giovanna Pellecchia; Victoria L Fell; SooIn Bae; Lakshmi Muthuswamy; Alessandro Datti; Sean E Egan; Zhe Jiang; Gustavo Leone; Gary D Bader; Aaron Schimmer; Eldad Zacksenhaus
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

10.  G1 arrest and differentiation can occur independently of Rb family function.

Authors:  Stacey E Wirt; Adam S Adler; Véronique Gebala; James M Weimann; Bethany E Schaffer; Louis A Saddic; Patrick Viatour; Hannes Vogel; Howard Y Chang; Alex Meissner; Julien Sage
Journal:  J Cell Biol       Date:  2010-11-08       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.